Future alternative therapies for β-thalassemia

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Beta-thalassemia is an inherited disorder caused by mutations in the beta-globin gene.
• It leads to anemia, iron overload, and ineffective erythropoiesis, necessitating blood transfusions.
• While screening has reduced cases in some regions, it's a growing global health issue.

Purpose of the Study:

• To review the current understanding of beta-thalassemia's molecular aspects and pathophysiological challenges.
• To highlight recent advancements in therapeutic approaches for beta-thalassemia.

Main Methods:

• Review of molecular biology, pathophysiology, and recent therapeutic studies on beta-thalassemia.
• Analysis of disease progression, complications, and management strategies.

Main Results:

• Understanding molecular mechanisms has improved screening and prenatal diagnosis, reducing major beta-thalassemia births in certain areas.
• Persistent challenges include ineffective erythropoiesis, iron overload, oxidative stress, splenomegaly, and thrombosis.
• Novel therapeutic strategies show promise in addressing these issues and minimizing transfusion needs.

Conclusions:

• Despite progress, beta-thalassemia remains a significant worldwide clinical problem with complex pathophysiology.
• Emerging therapies offer hope for improved management and reduced reliance on blood transfusions.
• Further research into molecular mechanisms is crucial for developing advanced treatments.